SCHEMBL30954045

SCHEMBL30954045

COc1c(Cl)cc2c(c1C(=O)O)OCCN2Cc1cccs1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.42
L3MBTL1 Q9Y468 2/20 0.38
USP2 O75604 1/20 0.38
GFER P55789 1/20 0.38
MAPT P10636 4/20 0.37
ALDH1A1 P00352 4/20 0.36
HSD17B10 Q99714 2/20 0.36
KDM4E B2RXH2 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
GAA P10253 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALOX15 P16050 1/20 0.36
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27433854 1.00 POLB (0.42) POLBL3MBTL1USP2GFERMAPT
SCHEMBL30954135 0.91 POLB (0.44) POLBL3MBTL1USP2GFERMAPT
SCHEMBL27433845 0.91 POLB (0.44) POLBL3MBTL1USP2GFERMAPT
SCHEMBL27435528 0.87 KCNA3 (0.41) ALDH1A1HSD17B10KDM4EDRD2DRD3
SCHEMBL30954048 0.83 ALDH1A1 (0.36) ALDH1A1HSD17B10KDM4ESMN1; SMN2DRD2
SCHEMBL27435420 0.83 ALDH1A1 (0.36) ALDH1A1HSD17B10KDM4ESMN1; SMN2DRD2
SCHEMBL30954067 0.83 TP53 (0.42) L3MBTL1MAPTALDH1A1HSD17B10KDM4E
SCHEMBL27435254 0.83 TP53 (0.42) L3MBTL1MAPTALDH1A1HSD17B10KDM4E
SCHEMBL30954041 0.83 CYP3A4 (0.38) USP2ALDH1A1HSD17B10KDM4E
SCHEMBL27435450 0.83 CYP3A4 (0.38) USP2ALDH1A1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP claimed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO claimed
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed